Pricing Log in Create free account
Saturday 7 November 2026 Export RANI’s income statement to Excel — free account

Rani Therapeutics Holdings, Inc.

RANI Healthcare Biotechnology

Rani Therapeutics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.6 million, up 58.9% from fiscal 2024.

Revenue
0.00%
EPS
+77.8%
Free cash flow
−55.3%

Quarter to June 2026, against a year earlier

0.54 0.02 +3.85%
Market cap
$72.0M
P/E
0.0×
Fwd P/E
−3.4×
Dividend yield
—
F-score
n/a
Altman Z
−1.33
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.05
Sold, $m 0.00
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — 2 — — — —
Sell — — — 1 — — — — — — — —
Insider Ownership 52.98%

Capital & Financial Ratios $m

Size
Market Cap 71.96
Revenue ttm 5.05
Net income ttm (33.42)
Free cash flow ttm (20.34)
Net debt Q (53.39)
Valuation
P/E 0.00
Forward P/E (3.40) (negative: loss-making)
Price / sales 20.02 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.11
Financial health
Current ratio Q 5.31 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (1,103.50)
Growth
Revenue growth Q 0.00%
Operating income growth Q +15.96% (above 0%: growing)
EPS, this year +61.11% (at or above 15%: strong)
EPS, next year A −8.57% (below 0%: weak)
Revenue, next year A +283.22% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +28.43% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 12.6×, against a ten-year median of 22.7×; over the ten years it ranged from 3.8× in 2023 to 222× in 2021.
P/S against its own 10 years 20.45%
10-year low 10-year high
P/B against its own 10 years 24.91%
10-year low 10-year high
EV/Sales against its own 10 years 14.79%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 49 28 50 53
Receivables — — 2 2
Inventory — — — —
Other — 0 — —
51 30 53 57
2023 2024 2025 Q'26
Payables 1 1 0 1
ST’ Debt 5 15 — —
Other — — — —
8 20 13 11

Compound Annual Growth %

10y 5y 3y
Sales — — 52.33%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (10.27%) (17.53%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.05 Actual −0.04

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.09 −0.12 Miss by 0.03
Q4 FY25 −0.03 −0.07 Miss by 0.04
Q1 FY26 −0.06 −0.04 Beat by 0.02
Q2 FY26 −0.05 −0.04 Beat by 0.01
Q3 FY26 −0.05 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.04) (0.04) — — —
’25 (0.22) (0.18) (0.12) (0.07) (0.45)
’24 (0.29) (0.26) (0.24) (0.27) (1.05)
’23 (0.33) (0.37) (0.36) (0.27) (1.33)
’22 (0.29) (0.31) (0.33) (0.35) (1.28)
’21 (0.28) (0.12) (0.16) (0.27) (0.43)
’20 (0.27) (0.06) (0.15) — (0.85)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 2 2 — — —
’25 0 — — 1 2
’24 — — — — 1
’21 1 2 — 0 3
’20 0 0 0 — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (9) — — —
’25 (8) (6) (5) 0 (19)
’24 (9) (9) (8) (9) (35)
’23 (12) (12) (14) (12) (51)
’22 (9) (10) (12) (15) (47)
’21 (4) (6) (11) (11) (32)
’20 (6) (9) 1 (7) (15)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (7) (9) — — —
’25 (8) (6) (5) 0 (19)
’24 (9) (9) (9) (9) (36)
’23 (12) (13) (15) (13) (52)
’22 (10) (11) (13) (15) (48)
’21 (4) (6) (11) (12) (33)
’20 (6) (10) 1 (7) (16)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 1 0 3 — — 1 2 5 +8.9% 6 7 14 +104.2%
Gross margin, % — — — 0.00 100.00 100.00 0.00 — 100.00 100.00 100.00 +100.0 pt
EBT — — — (27) (17) (53) (63) (68) (57) (41) (33) +7.5%
EBT margin, % — — — (2,715.73) (3,607.79) (1,952.41) 0.00 0.00 (5,504.28) (2,507.65) (661.99) +208.1 pt
Net income — 0 — (27) (17) (53) (63) (68) (57) (41) (33) n/m
Per share, $
Per share, $ Revenue — — — 0.05 0.02 0.14 0.00 0.00 0.04 0.02 0.03 (11.0%)
Earnings — — — (1.35) (0.85) (0.43) (1.28) (1.33) (1.05) (0.45) (0.27) (16.7%)
Cash flow — — — (1.33) (0.76) (1.65) (1.95) (2.01) (1.25) (0.28) (0.11) (22.7%)
Capex — — — 0.00 (0.06) (0.03) (0.07) (0.05) (0.01) 0.00 0.00 n/m
Free cash flow — — — (1.33) (0.82) (1.68) (2.02) (2.06) (1.26) (0.28) (0.11) (22.7%)
Book value — — — (4.90) 3.62 6.22 3.11 1.00 0.12 0.63 0.26 n/m
Shares, m — — — 20 20 20 24 26 28 66 120 +22.3%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 — — 0.00 0.00 0.00 0.0
P/S — — — 75.17 75.17 113.06 — — 13.81 24.84 20.02 60.4
P/B — — — 0.00 0.00 2.63 — — 11.17 2.15 2.11 3.2
EV/Sales — — — 118.71 118.71 140.48 — — 12.74 15.40 12.57 81.2
EV/FCF — — — (21.14) (21.14) (12.12) — — (1.01) (2.94) (3.12) (11.7)
Cash, $m
Cash, $m Operating cash flow — — — (26) (15) (32) (47) (51) (35) (19) (20) (5.5%)
Capex — — — (2) (1) (1) (2) (1) 0 0 0 (38.2%)
Free cash flow — — — (26) (16) (33) (48) (52) (36) (19) (20) (5.4%)
Balance, $m
Balance, $m Working capital — — — 13 70 117 96 43 10 41 46 +20.2%
Net debt — — — 99 (69) (117) (68) (19) (3) (50) (53) n/m
Shareholders’ equity — — — (97) 71 122 74 25 3 42 48 n/m
Returns, %
Returns, % ROA — — — (230.97) (32.61) (8.18) (26.34) (40.94) (63.50) (62.30) (77.54) +168.7 pt
ROIC — — — 0.00 (495.21) (783.89) (698.55) (657.31) (7,135.17) 0.00 0.00 0.0 pt
ROE — — — 25.32 15.91 (202.50) (31.28) (68.32) (207.48) (131.87) (155.24) (157.2) pt
People
People Employees — — — — 71 114 163 140 106 71 — 0.0%
Revenue/emp, $m — — — 0.00 0.01 0.02 0.00 0.00 0.01 0.02 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Rani Therapeutics Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NRXS Neuraxis, Inc. $76.7M — (loss-making) — (loss-making) +115.71% (above 0%: growing) n/m +29.76% (above 0%: growing) 85.87% (110.16%) Compare
CLLS Cellectis S.A. $74.5M — (loss-making) — −62.05% (below 0%: shrinking) n/m −36.95% (below 0%: shrinking) 100.00% (340.69%) Compare
OKYO OKYO Pharma Limited Sponsored ADR $73.5M — (loss-making) — — n/m +37.39% (above 0%: growing) 0.00% — Compare
TNYA Tenaya Therapeutics, Inc. $72.0M — (loss-making) — — n/m −13.18% (below 0%: shrinking) 100.00% (1,153.33%) Compare
RANI Rani Therapeutics Holdings, Inc. $72.0M — (loss-making) — (loss-making) 0.00% n/m −55.29% (below 0%: shrinking) 100.00% (516.86%)
MNOV MediciNova, Inc. $71.4M — (loss-making) — (loss-making) +240.56% (above 0%: growing) n/m +16.75% (above 0%: growing) 69.33% (554.36%) Compare
NTRB Nutriband Inc. $67.8M — (loss-making) 4.6× −29.72% (below 0%: shrinking) n/m +55.46% (above 0%: growing) 41.58% (203.57%) Compare
ACRV Acrivon Therapeutics, Inc. $67.3M — (loss-making) — — n/m +12.59% (above 0%: growing) 0.00% 0.00% Compare
CSBR Champions Oncology, Inc. $66.3M — (loss-making) — (loss-making) +8.84% (above 0%: growing) n/m −198.74% (below 0%: shrinking) 50.54% (2.69%) Compare
Median of peers $71.7M — — +8.84% — +14.67% 59.94% (203.57%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 16 April 2026

Ownership

Directors and executive officers, together 26.73%
Mir Imran 21.52%
InCube Labs, L.L.C. 18.12%
Samsara BioCapital, L.P. 7.90%
RA Capital Healthcare Fund, L.P. 7.90%
AWM Investment Company, Inc. 7.87%
Invus Global Management, L.L.C. 7.47%
SymBiosis Capital Partners, L.L.C. 5.09%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Rani Therapeutics Holdings, Inc. (RANI) Latest News

21 Oct

Impact 4 · · MarketBeat

5 Oct

Impact 4 · · GlobeNewswire

16 Aug

Impact 4 · · MarketBeat

13 Aug

Impact 3 ·

15 Jul

Impact 4 ·

9 Jul

Impact 4 ·

8 May

Impact 3 · · Simply Wall St.

9 Apr

Impact 3 · · GlobeNewswire

26 Mar

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

25 Mar

Impact 3 · · GlobeNewswire

28 Jan

Impact 3 · · GlobeNewswire

24 Jan

Impact 3 ·

8 Jan

Impact 4 · · GlobeNewswireBioPharma DiveMT Newswires

24 Nov

Impact 3 · · GlobeNewswire

10 Nov

Impact 3 · · Zacks Small Cap Research

6 Nov

Impact 4 · · GlobeNewswire

30 Oct

Impact 4 · · GlobeNewswire

26 Oct

Impact 4 · · Insider Monkey

23 Oct

Impact 4 ·
Impact 3 · · GlobeNewswire

20 Oct

Impact 4 · · Zacks Small Cap Research

19 Oct

Impact 4 · · Simply Wall St.

18 Oct

Impact 4 · · Simply Wall St.

17 Oct

Impact 4 · · GuruFocus.comMT NewswiresMT NewswiresGuruFocus.comStockStoryMT NewswiresSimply Wall St.MT Newswires
Impact 4 · · MT Newswires
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswireMT NewswiresMT NewswiresSimply Wall St.MT NewswiresMT NewswiresMT Newswires
Impact 3 · · MT Newswires

12 Aug

Impact 3 ·
stockrow.com/RANI · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com